Stanford Professor’s Lung Cancer Diagnosis Highlights Shift Toward Personalized mRNA Therapies

Stanford University medical professor Bryant Lin founded the school’s Center for Asian Health Research and Education with a focus on improving lung cancer screening, only to receive a Stage IV diagnosis of the disease two years ago. The irony was not lost on Lin, who now shares his experience with students while teaching classes on the subject.

“Super ironic that I would be co-leading the center that supports research and education in this disease, and I get diagnosed myself,” Lin said. Despite the severity of his condition, the non-smoker describes himself as hopeful, noting that the development of personalized precision therapeutics is creating a brighter future for patients.

Lin’s goal is to transform lung cancer from a fatal diagnosis into a chronic, manageable disease. Recent medical advancements are indeed beginning to shift survival statistics. While the five-year survival rate for all stages of lung cancer remains at 30%, it has doubled over the past three decades. For early-stage, localized cancer, the five-year survival rate reached 67% between 2015 and 2021.

Jonathan Goldman, an oncologist and researcher at UCLA, attributes much of this progress to genetic testing, which allows doctors to identify the specific mutations driving abnormal cell growth. This targeted approach enables the use of therapies designed for particular cancer subtypes, resulting in fewer side effects compared to traditional chemotherapy.

“Survival used to be under a year, and now it’s often several years and sometimes many years,” Goldman said. The increased effectiveness of targeted treatments, which focus attacks on specific mutated cells, marks a significant departure from the generalized therapies of the past.